Takeda targets next-gen treatments with Stanford tie-up

PureTech advancing milk-derived oligonucleotide platform with Roche
Credit: Shutterstock.com/ anyaivanova

A new partnership between Takeda Pharmaceutical and Stanford University is aiming to speed up the process of bringing new drugs to market.

The two organisations have formed the Alliance for Innovative Medicines (or AIM) which will help transform Stanford research into next-gen treatments.

AIM will begin taking proposals from Stanford labs from October.

“Stanford AIM’s purpose is to accelerate the translation of Stanford’s cutting-edge discoveries into real treatments for human disease,” said Chaitan Khosla, a professor of chemistry and chemical engineering and Director of Stanford ChEM-H.

He added: “Through the expertise and in-kind support from Takeda, Stanford faculty members will develop a more complete picture of how their fundamental discoveries might impact human health.

“The collaboration also ‘de-risks’ projects born at Stanford, making it much easier to license them out for further development.

“Takeda chemists will participate in cutting-edge research at one of the nation’s top research universities.”

Stanford will retain all intellectual property from Stanford AIM-supported research.